Pharmaceutical giant Pfizer has upgraded its COVID-19 vaccine sales for the year by more than double with higher global distribution and the expansion of shots to children, FT reported.

  • Pfizer now expects to raise $36 billion in sales this year, up from its $15 billion projection in February and $33.5 billion in July. It expects sales to hit $29 billion in 2022.
  • The company raised $13 billion in sales in the third quarter, with its four-week average market share up to 74% in the United States on October 31, and 80% in the European Union.
  • Pfizer has been criticized for the delays in shipments to developing countries such as Africa where only 6% of the population have been fully vaccinated.
  • Pfizer Chief Executive Albert Bourla said the firm is boosting supply to low and middle-income countries, with three-quarters of vaccine revenues coming from countries outside the US in the third quarter.